EPM
EUCRW

Equitec Proprietary Markets’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

Equitec Proprietary Markets’s Portfolio EUCRW Stock Details EUCRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-8,716
Closed -$9K – 311
2021
Q2 		$9K Buy
+8,716
New +$7.82K ﹤0.01% 236

Other funds holding EUCRW

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Equitec Proprietary Markets's EUCRW Position: Q3 2021 in Review

Equitec Proprietary Markets sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q3 2021, closing a stake of 8,716 shares — an estimated $9K sold.

Equitec Proprietary Markets first reported a position in EUCRW in Q2 2021 and held it in 1 quarter. The position peaked at $9K in Q2 2021. 17 funds tracked by Wall St. Rank hold EUCRW as of Q3 2021.

  • Equitec Proprietary Markets reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q3 2021 after selling out during the quarter.
  • Equitec Proprietary Markets sold 8,716 Eucrates Biomedical Acquisition Corp. Warrant shares in Q3 2021, an estimated $9K.
  • Equitec Proprietary Markets first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q2 2021 and held it in 1 quarter.
  • Equitec Proprietary Markets's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $9K in Q2 2021.
  • 17 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q3 2021.

Based on Equitec Proprietary Markets's 13F filing for Q3 2021, filed 12 Oct 2021.